Cardio3 BioSciences is a biotechnology company specializing in research and development for regenerative, protective, and reconstructive therapies for treating cardiac disorders (primarily heart failure and myocardial infarction).
Initial Public Offering
Subscription period :
From 21/06/2013 up to 03/07/2013 à 16h (Brussels and Paris time)
Centralisation date :
Pricing date / Annoucement of the IPO result :
04/07/2013 / A Euronext market notice will be issued on 04/07/2013
First trading date :
The trading will start on 05/07/2013 on an "As-if-andwhen- issued basis" under the product name "CARDIO3 PROMESSES". The trading of ordinary shares will start on 10/07/2013 under the product name "CARDIO3 BIO" (ISIN code and the trading symbol will remain the same).